BioCryst Pharmaceuticals, Inc. (BCRX)
| Previous close | 10.92 |
| Open | 11.08 |
| Bid | 10.43 x 800 |
| Ask | 10.44 x 800 |
| Day's range | 9.69 - 11.19 |
| 52-week range | 1.58 - 12.90 |
| Volume | 6,035,382 |
| Avg. volume | 7,869,415 |
| Market cap | 1.888B |
| Beta (5Y monthly) | 2.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.09 |
| Earnings date | 04 May 2021 - 10 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.78 |
- Motley Fool
Why BioCryst Pharmaceuticals Stock Is Popping Today
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are rising sharply today following bullish commentary from a Wall Street analyst. The biopharmaceutical company's stock was up by 9.2% as of 1:11 p.m. EST, after jumping by as much as 10.6% earlier on Monday. Cowen analyst Ken Cacciatore initiated coverage on BioCryst stock with an outperform (buy) rating.
- Motley Fool
Why BioCryst Pharmaceuticals Stock Is Falling Today
BioCryst Pharmaceuticals (NASDAQ: BCRX) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results. BioCryst's shares were down by 8.4% as of 1:53 p.m. EST. BioCryst's total revenue for the fourth quarter ending Dec. 31 was roughly $4 million, down from the $39.7 million in revenue recorded during the year-ago period.
- Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2020 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the BioCryst fourth-quarter 2020 earnings call. Participating with me today are CEO Jon Stonehouse, CFO Anthony Doyle, Chief Medical Officer, Dr.
